Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

on behalf of the ESMO Guidelines Committee

doi:10.1093/annonc/mdx223

Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

on behalf of the ESMO Guidelines Committee

Risultato della ricerca: Contributo su rivista › Articolo in rivista › peer review

Lingua originale	Inglese
pagine (da-a)	iv62-iv71
Rivista	Annals of Oncology
Volume	28
DOI	https://doi.org/10.1093/annonc/mdx223
Stato di pubblicazione	Pubblicato - 2017
Pubblicato esternamente	Sì

Accesso al documento

10.1093/annonc/mdx223

Altri file e collegamenti

Link to publication in Scopus

Cita questo

@article{30419faaf9514e67bce2d4f03d8db39d,

title = "Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up",

author = "{on behalf of the ESMO Guidelines Committee} and M. Dreyling and E. Campo and O. Hermine and M. Jerkeman and {Le Gouill}, S. and S. Rule and O. Shpilberg and J. Walewski and M. Ladetto",

note = "Funding Information: MD has reported being a member of the advisory board of Bayer, Celgene, Gilead, Janssen, Mundipharma, Sandoz and Roche, received honoraria from Bayer, Celgene, Gilead, Janssen and Roche and research grants from Celgene, Janssen, Mundipharma, Pfizer and Roche; MJ received research support from Janssen, Celgene, Giliead and Abbvie; SLG has reported research grants 16. and honoraria from Roche Genentech and Jenssen-Cilag and honoraria from Celgene; OS has reported to be a member of the scientific advisory board for Roche, AbbVie, Gilead sciences and Takeda; JW has reported advisory board for Roche, Janssen-Cilag, Celgene, Amgen, Bristol-Myers Squibb and Incyte, received lecture honoraria from Roche, Takeda, Celgene, Servier, Gilead and Janssen-Cilag, research funding from Roche, Mundipharma, Celgene and GlaxoSmithKline/Novartis, and travel grants from Roche, Celgene, Sanofi and Servier; EC, OH, SR and ML have reported no conflict of interest.",

year = "2017",

doi = "10.1093/annonc/mdx223",

language = "English",

volume = "28",

pages = "iv62--iv71",

journal = "Annals of Oncology",

issn = "0923-7534",

publisher = "Elsevier Ltd.",

}

TY - JOUR

T1 - Newly diagnosed and relapsed mantle cell lymphoma

T2 - ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

AU - on behalf of the ESMO Guidelines Committee

AU - Dreyling, M.

AU - Campo, E.

AU - Hermine, O.

AU - Jerkeman, M.

AU - Le Gouill, S.

AU - Rule, S.

AU - Shpilberg, O.

AU - Walewski, J.

AU - Ladetto, M.

N1 - Funding Information: MD has reported being a member of the advisory board of Bayer, Celgene, Gilead, Janssen, Mundipharma, Sandoz and Roche, received honoraria from Bayer, Celgene, Gilead, Janssen and Roche and research grants from Celgene, Janssen, Mundipharma, Pfizer and Roche; MJ received research support from Janssen, Celgene, Giliead and Abbvie; SLG has reported research grants 16. and honoraria from Roche Genentech and Jenssen-Cilag and honoraria from Celgene; OS has reported to be a member of the scientific advisory board for Roche, AbbVie, Gilead sciences and Takeda; JW has reported advisory board for Roche, Janssen-Cilag, Celgene, Amgen, Bristol-Myers Squibb and Incyte, received lecture honoraria from Roche, Takeda, Celgene, Servier, Gilead and Janssen-Cilag, research funding from Roche, Mundipharma, Celgene and GlaxoSmithKline/Novartis, and travel grants from Roche, Celgene, Sanofi and Servier; EC, OH, SR and ML have reported no conflict of interest.

PY - 2017

Y1 - 2017

UR - http://www.scopus.com/inward/record.url?scp=85029682231&partnerID=8YFLogxK

U2 - 10.1093/annonc/mdx223

DO - 10.1093/annonc/mdx223

M3 - Article

SN - 0923-7534

VL - 28

SP - iv62-iv71

JO - Annals of Oncology

JF - Annals of Oncology

ER -